Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

Cardinal Health (CAH) has significantly outperformed the broader Medical sector year-to-date, returning 32.8% while the sector experienced a 5.2% decline. The company holds a Zacks Rank #2 (Buy), bolstered by a 2.8% increase in its full-year earnings consensus estimate over the past quarter, indicating an improving outlook. This strong performance also surpasses its specific Medical - Dental Supplies industry, highlighting CAH as a standout within the healthcare landscape.

Analysis

Cardinal Health (CAH) has demonstrated significant market outperformance, delivering a 32.8% year-to-date return in a period where the broader Medical sector declined by an average of 5.2%. This performance also surpasses its specific Medical - Dental Supplies industry, which has lost 0.7% over the same period. The positive momentum is underpinned by improving fundamentals, as indicated by a Zacks Rank of #2 (Buy) and a 2.8% upward revision in its consensus full-year earnings estimate within the last quarter. This signals growing analyst confidence in the company's earnings outlook. For context, another sector outperformer, Biotricity Inc. (BTCY), has seen a 75.9% year-to-date gain, supported by a much larger 17.9% increase in its consensus EPS estimate and a similar #2 (Buy) rank. Notably, BTCY operates in the Medical Info Systems industry, which has grown 8.2% this year, whereas CAH is excelling within a contracting industry environment.

Key Decisions for Investors

• Given Cardinal Health's strong price momentum and positive analyst earnings revisions, investors with a bullish outlook on healthcare may consider the stock as a potential outperformer relative to its peers.
• It is crucial to recognize that CAH's outperformance is occurring despite weakness in its direct industry and the broader medical sector, highlighting company-specific factors that investors should continue to monitor closely.
• For those seeking higher-growth opportunities within the medical field, Biotricity Inc. (BTCY) warrants attention due to its superior year-to-date returns and more substantial upward earnings estimate revisions.
• Investors should track future earnings estimate revisions for both CAH and BTCY, as the current positive sentiment is heavily predicated on this improving outlook.